Introduction

In mammals, maintaining extracellular potassium ion concentration, [K\(^+\)], within a narrow range is essential for normal cell functions and the ability to sustain life (1). The problem of tight [K\(^+\)] regulation is compounded by the fact that extracellular K\(^+\) is a small fraction of total body K\(^+\), and hence [K\(^+\)] could in principle be subject to large fluctuations, particularly in the face of a sudden increase in intake. Thus, mammals have developed efficient mechanisms to respond to changes in extracellular [K\(^+\)], substantially through rapid and profound changes in K\(^+\) excretion by the kidneys. A combination of systemic (predominantly hormonal) and local renal signaling mechanisms have evolved to rapidly alter K\(^+\) secretion into the kidney tubule lumen by principal cells (PCs) of the distal segment frequently referred to as the aldosterone-sensitive distal nephron (ASDN). The apical translocation of K\(^+\) into the tubule lumen of PCs is mediated predominantly by the renal outer medullary K\(^+\) channel (ROMK). The epithelial Na\(^+\) channel (ENaC), which depolarizes the apical membrane, is central to establishing the driving force for K\(^+\) movement (1, 2). Hormonal regulation of this process is predominantly by aldosterone, a steroid hormone, which acts through the mineralocorticoid receptor (MR) to regulate the transcription of multiple genes that control ENaC activity (3).

A key target of MR gene regulation is the serine-threonine kinase SGK1, which stimulates apical localization of ENaC and enhances electrogenic Na\(^+\) reabsorption (4). The absence or inhibition of SGK1 activity results in Na\(^+\) wasting and hyperkalemia in mice, despite markedly elevated aldosterone, which recapitulates many of the features of MR deficiency (5). To be activated, SGK1 must undergo phosphorylation within a short hydrophobic motif (HM) near its C-terminus, which is mediated by the kinase mTOR, specifically in its type 2 multiprotein complex, mTORC2 (6). The importance of mTORC2-dependent SGK1 phosphorylation in regulating ENaC activity and K\(^+\) excretion is well established (7–9); however, the physiologically relevant control mechanisms have remained poorly characterized.
Additional genetic and physiological evidence also supports the idea that K⁺ acts through non–aldosterone-dependent mechanisms to regulate K⁺ excretion. Notably, even in the complete absence of aldosterone in mice (due to aldosterone synthase gene deletion), the K⁺ excretory response to moderate changes in K⁺ intake is near-normal (10). Similarly, dogs subjected to adrenalectomy and maintained on a low fixed level of aldosterone respond effectively to KCl infusion with increased K⁺ excretion, which is further stimulated by exogenous aldosterone (11). One mechanism that contributes to this aldosterone-independent regulation is the local effect of [K⁺] to directly inhibit reabsorption of Na⁺ and Cl⁻ in the distal convoluted tubule of the kidney (12–14), a tubule segment just upstream of the ENaC-expressing ASDN. Na⁺ and Cl⁻ are reabsorbed together in an electroneutral fashion in this nephron segment by the sodium chloride cotransporter (NCC) (15). Its inhibition allows more Na⁺ to pass to tubular segments further downstream where ENaC-mediated Na⁺ reabsorption establishes the lumen negative potential driving K⁺ secretion (12, 16, 17). However, pharmacologic inhibition of NCC is insufficient to enhance K⁺ excretion, despite a marked increase in Na⁺ delivery to the ASDN (18, 19); this stands in marked contrast to a KCl load, which rapidly stimulates both natriuresis and marked kaliuresis (12, 20).

Taken together, these observations suggested the hypothesis that an acute K⁺ load acts to stimulate ENaC activity in PCs, and that this effect precedes and then is augmented by the ENaC-stimulatory effects of aldosterone. We further hypothesized that the mTORC2/SGK1 signaling module mediates these direct K⁺ effects, and integrates them with those of aldosterone. Our present data, based on in vivo balance studies, kidney tubule patch-clamp experiments, and cell culture ion transport and kinase signaling studies support the idea that K⁺ acts through basolateral membrane K⁺ channels of PCs to stimulate apical membrane ENaC activity by enhancing mTORC2-mediated phosphorylation of SGK1. Our data further implicate WNK1 as an essential component of this signaling pathway, interestingly, independently of its kinase activity. We propose a model in which a WNK1/mTORC2/SGK1 signaling module integrates the effects of aldosterone with local effects of K⁺ to regulate K⁺ secretion and maintain K⁺ homeostasis.

Results

KCl gavage or intravenous infusion acutely stimulates ENaC-dependent Na⁺ transport in mice. In order to assess the role of ENaC activity in the regulation of K⁺ secretion in mice, we examined the effect of K⁺ on ENaC-mediated Na⁺ reabsorption, using the highly specific ENaC inhibitor benzamil. The difference between Na⁺ excretion in the presence and absence of intraperitoneal (i.p.) benzamil injection (benzamil-induced natriuresis [BIN]) has been widely used as a reflection of the amount of Na⁺ that is being reabsorbed via ENaC (20, 21). K⁺, administered by gavage, stimulates BIN in both male NMRI and female C57BL/6 mice (data summarized in Table 1). In the male NMRI mice receiving a K⁺-free gavage, pretreatment with benzamil induced a
natriuresis of 1.8 ± 0.4 μmol Na+/g BW over 4 hours (Figure 1A, difference between vehicle and benzamil curves). The BIN was approximately 3-fold greater (5.7 ± 0.9 μmol Na+/g BW over 4 hours) in mice receiving KCl gavage (10 μmol K+/g BW) (Figure 1B). The effect in spot urine collection was significant as early as 30–60 minutes after K+ load (Figure 1B). A similar effect of KCl was observed in female C57BL/6 mice (Table 1). That this stimulatory effect of KCl on ENaC activity is linked to increased K+ excretion can be seen as benzamil-suppressible kaliuresis. Consistent with earlier reports (22), K+ excretion was stimulated 5-fold by KCl gavage (from 1.8 ± 0.4 to 9.5 ± 1.2), and this effect was markedly reduced by benzamil (Figure 1, C and D, and Table 1). During this early-phase response, we did not detect a change in total ENaC subunit protein or α- and γ-ENaC cleavage products in the kidneys harvested 1 hour after gavage (Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.126910DS1).

To investigate if the effect of KCl load relies on signals originating from the GI tract, and to better assess the kinetics, we infused KCl directly into tail veins of anesthetized mice with urine collected via bladder catheter. An acute shift of infusion from NaCl to KCl resulted in a significant 2-fold increase in BIN within 25 minutes, while Na+ excretion in the vehicle-treated mice was not altered (compare benzamil- and vehicle-treated groups in Figure 1, E and F). As with the gavaged mice, intravenous infusion of KCl also induced kaliuresis, which was markedly suppressible by benzamil (Figure 1, G and H).

KCl-mediated increase of BIN is not a product of augmented Na+ delivery to ENaC. The above data support the conclusion that KCl gavage or infusion stimulates ENaC as reflected by increased BIN. Furthermore, this activation of ENaC is essential for enhancing K+ excretion as reflected by the marked reduction in K+ excretion in benzamil-treated mice (Figure 1D). Previous work supports the conclusion that selectively increasing Na+ delivery by inhibiting NCC with thiazides is not sufficient to enhance ENaC-dependent K+ excretion (18), consistent with the idea that activation of ENaC per se is necessary. In order to further investigate the potential role of increased Na+ delivery to the channel, we administered NaCl by gavage to induce natriuresis without inducing hypovolemia. Under these conditions, NaCl induced a marked natriuresis (significantly greater than that induced by KCl) (Supplemental Figure 2); however, in sharp contrast

Figure 1. Systemic K+ loading acutely increases benzamil-inducible urinary Na+ loss. (A and B) Cumulative Na+ excretion relative to BW during 4 hours following control (A) or KCl (B) gavage in vehicle- versus benzamil-treated mice. Differences between the curves (marked with black bracket) represent benzamil-induced natriuresis (BIN). (C and D) Cumulative K+ excretion relative to BW during the first 4 hours after control (C) or KCl (D) gavage in vehicle- versus benzamil-treated mice. Differences between the curves (marked with red bracket) represent benzamil-suppressible kaliuresis. Dashed line indicates K+ load given. (E and F) Cumulative Na+ excretion during the first 30 minutes following intravenous saline control (E) or KCl (F) infusion in vehicle- versus benzamil-treated mice. Differences between the curves (marked with black bracket) represent BIN. (G and H) Cumulative K+ excretion during the first 30 minutes following intravenous saline control (G) or KCl infusion (H) in vehicle- versus benzamil-treated mice. Differences between the curves (marked with red bracket) represent benzamil-suppressible kaliuresis. In all panels, (▲) represents vehicle- and (■) represents benzamil-treated mice. *P < 0.05 between vehicle and benzamil. $P < 0.05 between KCl and control loading by 2-way ANOVA with Bonferroni’s multiple-comparison test. n = 6 in all presented data.
to KCl (Figure 1, A and B), it did not stimulate BIN (Figure 2, A and B). Thus, increased delivery of Na+ to ENaC does not by itself alter BIN.

Acute KCl stimulation of ENaC is MR independent. Together with prior literature, the above findings support the conclusion that K+-induced K+ excretion requires ENaC stimulation. As noted above, it is well established that K+ stimulates aldosterone secretion by the adrenal cortex, and that aldosterone acts in turn through the MR to stimulate ENaC (3). This effect is clearly important for long-term responses to large K+ loads; however, it may not be necessary for the early response to more physiological K+ loads (10, 11). In support of the idea that the rapid activation of ENaC by KCl (Figure 1, B and F) was not elicited by aldosterone, we found that plasma aldosterone levels in mice receiving control versus KCl were not significantly different 1 hour after gavage (Table 1). We then went on to directly assess the role of MR using the MR antagonist eplerenone. As shown in Figure 2, C and D, we found that KCl still stimulated BIN in mice pretreated with eplerenone (compare Figure 2, C and D). Indeed, the effect of KCl in mice treated with eplerenone was not significantly different from its effect in vehicle-treated controls (compare Figure 1, B and D).

Effect of extracellular [K+] on ENaC activity in native mouse CCD and cultured CCD cells. The above data strongly support the idea that K+ can act independently of changes in aldosterone, MR activation, or signaling from the GI tract to rapidly modulate ENaC and regulate its own excretion. In order to begin to address the underlying mechanism, we next performed in vitro patch-clamp experiments on freshly isolated cortical collecting duct (CCD). Mouse CCD was dissected in normal K+ buffer (5 mM) as described previously (23), tubules were split open, and whole-cell patch conditions were established. After achieving a stable current at –60 mV, extracellular [K+] was reduced to 1 mM by replacing 4 mM of the KCl with NaCl, with all other buffer conditions unchanged. As shown in Figure 3A, reducing bath [K+] to 1 mM resulted in a significant decrease in amiloride-sensitive current measured after approximately 15 minutes, consistent with the in vivo results.

We next examined the effect of changing [K+] in mpkCCD cells, a stable cell line that reproduces all of the key features of native CCD (24). In initial experiments, in order to achieve maximal distinction between low and high [K+], we adapted the cells to DMEM containing 1 mM KCl and 144 mM NaCl without serum for 2 hours. At t = 0, the medium was changed to the K+ concentrations shown (Figure 3B), with inverse change of [Na+] to maintain constant osmolarity and total cation concentration. Consistent with both the in vivo balance studies and patch-clamp experiments, amiloride-sensitive current increased by 47% ± 0.27% when [K+] was increased to 3 mM and by 88% ± 1.58% when increased to 5 mM. Interestingly, there was no further increase in current when [K+] was increased to 6, 7 (Figure 3B), or 10 mM (data not shown). Similar results were obtained when K+ was replaced by choline chloride rather than NaCl (data not shown). An inverse effect was found when cells were adapted to 5 mM K+ and shifted to 1 mM (data not shown), consistent with the patch-clamp results in intact tubule.

In order to examine more physiologically relevant K+ concentrations, comparable to those achieved in the in vivo experiments, we adapted the mpkCCD cells to 3 mM K+, and then added KCl to bring the [K+] up to 6 mM. As shown in Figure 3C, a significant increase in ENaC current was seen. The effects were less dramatic than...
those seen with larger changes in $[\text{K}^+]$, but were consistent and highly statistically significant. Together, these data strongly support a direct local effect of $\text{K}^+$ to stimulate $\text{ENaC}$ by increasing $\text{SGK1}$ activity in CCD cells.

$\text{SGK1}$ activity is required for $\text{K}^+$ stimulation of $\text{ENaC}$. Previous literature has established that $\text{SGK1}$ is an important regulator of $\text{ENaC}$, and mediator of effects of aldosterone to stimulate $\text{K}^+$ excretion (25). $\text{SGK1}$ stimulates $\text{ENaC}$ in a variety of experimental systems (25), and $\text{SGK1}$-KO mice fail to appropriately activate $\text{ENaC}$ in response to increased dietary $\text{K}^+$, and become hyperkalemic despite marked elevation of aldosterone (26). It is well established both in vitro and in vivo that $\text{mTOR}$ is required for $\text{ENaC}$ activity, and that its effects proceed at least in part through $\text{SGK1}$, which it phosphorylates within its C-terminal HM (7). Some activators of $\text{mTOR}$-dependent HM phosphorylation such as insulin and growth factors have been identified (4, 7); however, the role of regulated HM phosphorylation in physiological feedback mechanisms, particularly those that control extracellular $[\text{K}^+]$, remains poorly characterized. With these considerations in mind, we first examined whether changing $[\text{K}^+]$ altered $\text{SGK1}$ HM phosphorylation. Immunoblots from the $\text{mpkCCD}$ cells in Figure 3, B and C, were prepared and stained with anti–phospho-$\text{SGK1}$ S422. As shown in Figure 4, A and B, $\text{SGK1}$ S422 phosphorylation increased proportionately to the increase in amiloride-sensitive current (Figure 3, B and C, respectively), consistent with a role for $\text{SGK1}$ HM phosphorylation in $\text{ENaC}$ stimulation by $\text{K}^+$.

A role for $\text{SGK1}$ to stimulate $\text{ENaC}$ in response to local changes in extracellular $[\text{K}^+]$ was further supported by the effects of $\text{SGK1}$ inhibition with GSK650394 (27), which blocked the increase in current induced by shifting media $[\text{K}^+]$ from 1 mM to 5 or 8 mM (Figure 4C) and from 3 mM to 6 mM (Figure 4D).

$mTORC2$ activity is required for $\text{K}^+$-stimulated $\text{SGK1}$ phosphorylation and activation of $\text{ENaC}$ in native $\text{CCD}$ and cultured cells. We next asked if $\text{mTOR}$-dependent phosphorylation of $\text{SGK1}$ is required for $\text{K}^+$-stimulated activation of $\text{ENaC}$ by performing a series of inhibitor and knockout experiments in native tubules and cultured cells. We first performed patch-clamp experiments in native $\text{CCD}$ treated with AZD8055, a potent and specific inhibitor of $\text{mTOR}$ in both of its major complexes, $\text{mTORC1}$...
and mTORC2. As shown in Figure 5A and Supplemental Table 1, AZD8055 suppressed current, as previously described (8), and abolished the difference in amiloride-sensitive current seen in 1 versus 5 mM K⁺. Similarly, in mpkCCD cells, AZD8055 blocked the ENaC-stimulatory effect of increasing [K+] from 1 to 5 mM (Figure 5B), in parallel with blocking SGK1 S422 phosphorylation (Figure 5C). A chemically unrelated mTOR inhibitor, PP242 (7), had a similar effect (data not shown).

mTORC1 and mTORC2 both contain mTOR, but due to the specificity conferred by associated proteins such as Raptor (mTORC1), Rictor (mTORC2), and mSin1 (mTORC2), they respond to distinct stimuli and phosphorylate distinct targets (28). The bulk of data support the idea that under most conditions SGK1 is phosphorylated by mTORC2 (6, 7, 29). However, there are data suggesting that in some cases SGK1 is phosphorylated by mTORC1 (30, 31). To address this issue in the context of K⁺ regulation, we treated the mpkCCD cells with the mTORC1-specific inhibitor rapamycin, which had no effect on K⁺-induced current.

---

**Figure 4. SGK1 activity is required for K⁺ stimulation of ENaC.** (A and B) K⁺ stimulates SGK1 phosphorylation in mpkCCD cells. Cells from Figure 3, B and C, were lyed and prepared for Western blot, and stained with antibodies as indicated. Upper panels: Western blot images showing blots stained with anti-phospho-SGK1 S422, total SGK1, and α-tubulin as labeled. Lower panels: Quantitation of phospho-SGK1/total SGK1 (as described in Methods). Data are mean ± SEM from 3 independent experiments. *P < 0.05, ****P < 0.0001 by 1-way ANOVA (A, lower panel). NS, not significant. *P < 0.05 by 2-tailed Student’s t test (B, lower panel). (C and D) Inhibition of SGK1 activity decreases K⁺-induced ENaC activity. mpkCCD cells were adapted to 1 mM (C) or 3 mM (D) extracellular [K⁺] as in Figure 3, B and C. The SGK1 inhibitor GSK650394 or vehicle was added and extracellular [K⁺] was then increased by addition of KCl for 1 hour prior to determining amiloride-sensitive Na⁺ current. Data are mean ± SEM from 3 independent experiments. ***P < 0.001, ****P < 0.0001 by 1-way ANOVA. μA, microamperes.
or SGK1 phosphorylation (data not shown). This result is consistent with the idea that the K\(^+\) effect is mediated by mTORC2; however, the possibility remains that mTORC1 and mTORC2 are redundant in this regard, and both must be inhibited (as by AZD8055). In the absence of a specific pharmacologic inhibitor of mTORC2, we used the CRISPR-Cas9 system to knock out the mTORC2-specific component, mSin1 in HEK-293T cells, as described previously (32). We found that WT HEK-293T cells (SIN1\(^+/+\)) respond to an increase in extracellular [K\(^+\)] with a robust increase in SGK1 phosphorylation (Supplemental Figure 3), which was lost in the mSin1-KO (HEK-293T SIN1\(^{-/-}\)) cells. Notably, phosphorylation of the mTORC1-specific target p70-S6 kinase was unaffected (data not shown; ref. 32). Transient transfection of mSin1 restored the effect of K\(^+\). In contrast, despite being mTORC2 dependent, phosphorylation of Akt (a close relative of SGK1) at S473 was unaffected by changes in [K\(^+\)] (Supplemental Figure 3). Together with the native-tubule and mpkCCD data, these data strongly support the idea that K\(^+\) acts locally within PCs to stimulate mTORC2-dependent SGK1 phosphorylation and thereby increase ENaC activity. Interestingly, this effect does not reflect generalized activation of mTORC2, but rather selective activity toward SGK1.

**Effects of [K\(^+\)] on ENaC are mediated by basolateral K\(^+\) channels, most likely Kir4.1/5.1.** The basolateral — but not the apical — membranes of PCs are exposed to K\(^+\) concentrations that reflect plasma levels.
Thus, a physiologically relevant effect on ENaC should be triggered by changing [K+] on the basolateral but not the apical side of the cells. We tested this by selectively altering basolateral versus apical [K+] in Transwells. As shown in Figure 6, in mpkCCD cells, ENaC current (Figure 6A) and SGK1 phosphorylation (Figure 6B) were stimulated by increasing basolateral but not apical [K+], while an inverse effect was elicited by selectively decreasing basolateral [K+] (Supplemental Figure 4).

The resting potential of PC basolateral membranes is dominated by K+ channels, predominantly, Kir4.1/5.1 (33). In order to determine if basolateral K+ channels were implicated in the effects of [K+], we treated mpkCCD cells adapted to 1 mM [K+] with BaCl2 on the basolateral side, just prior to changing [K+], which was either raised to 5 mM or kept at 1 mM (Figure 7, A and B). In cells maintained in 1 mM K+, addition of Ba2+ stimulated amiloride-sensitive current (Figure 7A) and SGK1 phosphorylation (Figure 7B) comparably to raising [K+] to 5 mM. Ba2+ did not provide additional stimulation beyond that of 5 mM [K+], further supporting the conclusion that the effects of this signaling system plateau at K+ concentrations in the high physiologic range. We further addressed the specific K+ channel(s) by treating the cells with a

Figure 6. SGK1 phosphorylation and ENaC current are regulated by basolateral [K+]. (A) Effect on amiloride-sensitive current of changing apical (left panel) versus basolateral (right panel) [K+] from 1 mM to 5 mM in mpkCCD cells. Data are presented as mean ± SEM. *P < 0.05 by 2-tailed Student’s t test. NS, not significant. (B) Effect on endogenous p-SGK1 S422 level of changing apical versus basolateral [K+] from 1 mM to 5 mM. Upper panel: Western blot images showing blots stained with anti–phospho-SGK1 S422, and total SGK1 as labeled. Lower panels: Quantitation of phospho-SGK1/total SGK1 in response to changes in apical (left panel) versus basolateral (right panel) [K+] (as described in Methods). Data are presented as mean ± SEM. *P < 0.05 by 2-tailed Student’s t test. Raising basolateral but not apical [K+] stimulates SGK1 S422 phosphorylation and Na+ current.
newly developed inhibitor specific for Kir4.1, VU0134992 (ref. 34 and Figure 7, C and D). The effects found were similar to those of Ba2+, providing strong support for the idea that Kir4.1 (probably in the form of the heteromultimer Kir4.1/5.1) is part of a signaling system that mediates direct sensing of [K+] by the ASDN.

Potential role of WNK1 in linking changes of basolateral [K+] to SGK1 activation

The foregoing data support a mechanistic picture in which changes in basolateral [K+] alter the K+ reversal potential, which results in altered membrane potential as K+ moves through Kir4.1/5.1 channels. This somehow results in altered mTORC2-dependent phosphorylation of SGK1, with a concomitant change in ENaC activation by Nedd4-2. However, the mechanism by which a change in membrane potential alters mTORC2-dependent SGK1 phosphorylation is still unclear. In this context, the recently described effect of [K+] to alter WNK kinase activities in the distal convoluted tubule (DCT) might be relevant. WNKs are well known for their central role in a kinase cascade that proceeds through phosphorylation of the kinase SPAK, which in turn phosphorylates and activates NCC (35). Low [K+] stimulates — and high K+ inhibits — this activity, at least in...
part by altering the intracellular concentration of Cl\(^-\) (14). WNK1 and WNK4 both bind Cl\(^-\), which inhibits their kinase activities (36). Other studies have suggested a role for WNKs in regulating K\(^+\) secretion within the ASDN, which expresses high levels of WNK1, and moderate levels of WNK4 (37, 38).

As a first step toward assessing a potential role of WNKs in mediating the effects of [K\(^+\)] on SGK1, we examined SGK1 phosphorylation in WNK1-deficient HEK-293T cells (HEK-293T WNK1\(^{-/-}\)) (39). K\(^+\)-stimulated SGK1 phosphorylation was nearly undetectable in these cells, and was fully rescued by heterologous WT or kinase-dead (K233M) WNK1 (residues 1–491) (Figure 8, A and B). In contrast, Akt phosphorylation (S473) (also mTORC2 dependent; Figure 8A and ref. 40) was unaffected by elimination of WNK1. Thus, the effect of WNK1 is not a generalized effect on mTORC2, but rather selectively modulates its activity toward SGK1. These findings are consistent with a role of WNK1 acting through a noncatalytic mechanism to modulate K\(^+\)-regulated mTORC2-dependent SGK1 phosphorylation, as shown schematically in Figure 9.

Discussion
It is well established that mammals respond to an acute K\(^+\) load with a profound and rapid increase in secretory K\(^+\) excretion, which is mediated almost entirely by the distal segments of the renal tubules, and occurs through apical membrane K\(^+\) channels (1). The driving force for apical K\(^+\) movement is established by electrogenic Na\(^+\) transport through ENaC (22). The steroid hormone aldosterone is essential for this process to proceed normally, particularly with chronic K\(^+\) loading or when large quantities of K\(^+\) must be excreted (10, 41). However, increasing evidence supports the idea that regulated K\(^+\) secretion can occur to a significant extent independently of changes in aldosterone, particularly in response to the kind of K\(^+\) load seen with a naturally occurring K\(^+\)-rich meal (10, 11, 42). Recent data support the idea that direct inhibition by K\(^+\) of electroneutral Na\(^+\)-Cl\(^-\) cotransport via NCC contributes to K\(^+\) secretion by enhancing Na\(^+\) delivery to the ENaC-expressing, K\(^+\)-secretory segments (12, 14, 16, 43). However, NCC inhibition by itself is not sufficient for this rapid effect (18). Together, these observations suggest the hypothesis that ENaC might be acutely activated by local changes in [K\(^+\)].

Our present data strongly support the idea that K\(^+\) is sensed and acts locally within PCs, independently of changes in aldosterone, to rapidly stimulate ENaC and thereby enhance its own secretion. First, we find in mice that a K\(^+\) load begins to enhance benzamil-inducible Na\(^+\) excretion (a reflection of ENaC activity) prior to significant change in aldosterone level, and that a substantial proportion of this early effect remains intact in the face of pharmacologic blockade of MR. This increase in ENaC activity also
is not due to increased Na⁺ delivery to the channel, in that it is not duplicated by increasing Na⁺ load. Second, in patch-clamp experiments on isolated CCDs, selectively lowering [K⁺] inhibits ENaC activity. Third, in cultured CCD cells, raising basolateral [K⁺] in the culture medium rapidly stimulates — and lowering [K⁺] inhibits — amiloride-sensitive Na⁺ current. That these acute effects on ENaC are implicated in controlling K⁺ excretion in vivo is supported by the observation that benzamil inhibits K⁺ excretion with a time course and extent that parallel its stimulation of Na⁺ excretion (compare Figure 1, B and D), similar to prior reports (22).

As a first step toward characterizing the mechanism underlying this local regulation, we have shown in cultured CCD cells grown on Transwell filters that the effect is seen only with manipulation of basolateral (but not luminal) [K⁺]. We further observed that inhibition of basolateral K⁺ channels with either the nonspecific K⁺-channel inhibitor, Ba²⁺, or with a specific inhibitor of Kir4.1 (VU0134992), mimics the effect of high [K⁺], supporting the idea that Kir4.1-dependent basolateral membrane potential is integral to the underlying mechanism.

Our data further establish the central importance of the mTORC2/SGK1 signaling module in mediating these effects. SGK1 is a well-established ENaC regulator, which is under dual regulation; its gene expression is rapidly and potently stimulated by aldosterone, the biosynthesis of which is tightly regulated by [K⁺]. Aldosterone acts through MR to stimulate SGK1 gene transcription, and ultimately control its level of protein expression. However, SGK1 kinase activity requires mTORC2-dependent phosphorylation at S422 (within its C-terminal HM) (6), and acute inhibition of mTOR inhibits ENaC in both cultured cells (7) and in vivo (8). ENaC is stimulated substantially through the effect of SGK1 to phosphorylate and thus inhibit the ubiquitin ligase Nedd4-2 (44), although other effects of SGK1 to regulate ENaC may contribute:

Figure 9. Model of Na⁺ and K⁺ transport regulation by local and systemic [K⁺] in PCs of the CCD. Cellular model of the integrated regulation of ENaC activity, and ENaC-dependent K⁺ secretion, in response to altered plasma K⁺. Green arrows indicate stimulatory effects. Red arrow indicates inhibitory effect. Solid arrows indicate rapid direct effects (seconds to minutes), dashed arrows indicate slower genomic effects (minutes to hours). According to this scheme, elevation of basolateral [K⁺] triggers membrane depolarization by altering the K⁺ channel–dominated resting potential, which with a possible involvement of intracellular [Cl⁻] and WNK1 stimulates mTORC2-dependent SGK1 activation via HM phosphorylation. Activated SGK1 stimulates ENaC predominately by inhibiting Nedd4-2, but also potentially through other effects including ENaC phosphorylation. The ensuing increase in electrogenic Na⁺ transport enhances K⁺ secretion via K⁺ channels, predominantly renal outer medullary K⁺ (ROMK) channels, but also large-conductance Ca²⁺-activated K⁺ (BK) channels. According to the model, SGK1 acts as a signal integrator, responding both to local signals that increase its activity, and to systemic hormonal signals (primarily aldosterone), which increase its expression.
for example, direct phosphorylation of the channel (45). We find that K⁺ stimulates mTORC2-dependent SGK1 phosphorylation, and that this effect is required for activation of ENaC. In addition to ENaC, it is also important to note that a role for regulation of K⁺ channels themselves, in particular ROMK, cannot be ruled out (46). Indeed, one recent report found that genetic disruption of mTORC2 (via constitutive Rictor knockout) caused hyperkalemia by disrupting both ENaC and ROMK (9). Although this may play a role in chronic regulation, the bulk of evidence supports the idea that acute regulation proceeds predominantly through ENaC-dependent control of the electrical gradient that drives K⁺ secretion (22).

It is interesting to note the similarities and differences between our present findings and those of other groups focusing on K⁺ effects in the DCT (47–49). In both cases, changing [K⁺] has cell-autonomous effects on apical transporters: ENaC on the one hand, NCC on the other. In both cases, the effect appears to be induced by basolateral but not apical changes in [K⁺], and to depend on basolateral K⁺ channels (possibly Kir4.1/5.1; ref. 50). However, in the 2 cases, the effects of K⁺ are opposite: NCC is inhibited by high [K⁺], ENaC is stimulated. Both of these effects are physiologically rational; however, the mechanistic bases must diverge. WNK proteins play a well-established role to mediate K⁺-induced inhibition of NCC, while our present data suggest that WNK1 (and potentially WNK4) plays a key role in the effects of K⁺ to selectively stimulate mTORC2 phosphorylation of SGK1 (Figure 8). In striking contrast to K⁺ regulation of SPAK and NCC, the K⁺ effect on SGK1 phosphorylation does not require WNK1 kinase activity (Figure 8). Furthermore, the effect appears to be specific for SGK1, and not a generalized activation of mTORC2 because SGK1’s close relative, Akt2 (also a substrate for mTORC2), is unaffected (Figure 8A and ref. 40). This latter observation is reminiscent of our recent findings that angiotensin II selectively stimulates SGK1 but not Akt phosphorylation (32). Of further interest, we found that changes in subcellular localization were central to this selective regulation; hormone-induced movement of mTORC2 and SGK1 from a perinuclear to plasma membrane location was required for selective regulation. With this in mind, it is notable that recent work from Boyd-Shiwarski et al. (51) demonstrated similar changes in WNK bodies in response to K⁺, in both DCT and connecting tubule cells. It will be of interest to explore these relationships in future work. Taken together with prior work from Cobb and colleagues (37), our present findings suggest that WNK1 serves as a K⁺-regulated scaffold that promotes mTORC2-dependent phosphorylation of SGK1, within the ENaC regulatory complex (52) (Figure 9). Although it is appealing to speculate that Cl⁻ binding to WNK1 plays a role as it does in NCC regulation (14, 36), our current data are ambiguous. In any case, our present data suggest a parsimonious explanation for shifting Na⁺ transport from electroneutral to electrogenic, particularly in DCT2 cells, which express both NCC and ENaC. Further experiments are needed to explore the role of Cl⁻ and to characterize the precise mechanism of this WNK-mTORC2/SGK1 signaling module.

Methods

Please see supplemental material for additional details.

Mice

In vivo experiments performed in unanesthetized animals. We used male (NMRI) mice and as a control for gender- or strain-specific effects female (C57BL/6) mice. All mice were purchased from Janvier Labs. Mice were transported to Aarhus in a temperature-controlled (21°C) car. Animals were acclimatized to the housing facility in Aarhus for at least 1 week before use in experiments. The mice were fed a control diet (ssniff EF R/M Control diet (0.9% K⁺ and 0.2% Na⁺) (ssniff Spezialdiäten).

Infusion and native CCD patch-clamp experiments. Male C57BL/6 mice were used. The mice were fed a low-sodium diet for 10 days (TD90228, 0.01%–0.02% NaCl) prior to experiments.

All mice experienced a 12-hour light/12-hour dark cycle and had access to normal drinking water and a control diet ad libitum. All mice were 8 to 12 weeks of age at the time of the experiments. In order to prevent circadian aldosterone fluctuations from affecting our data, all animal experiments were started at 9 am.

Electrolyte gavage

Mice were either given a K⁺, Na⁺, or control gavage. To initiate a prandial metabolic response, i.e., rise in insulin, all gavages contained 2% max glucose. The K⁺ gavage contained 2% max K⁺ (512 mM) and Cl⁻. This maneuver is well described to increase plasma K⁺, reduce NCC phosphorylation, and induce natriuresis and kaliuresis acutely (12, 20). The Na⁺ gavage had the same osmolarity (512 mM) and Cl⁻ concentration.
as the K⁺ gavage. The control gavage only contained glucose. The mice received a volume of 20 μl/g BW and a total K⁺ load that corresponds to approximately 25% of daily K⁺ intake (53). Gavage was always given at 9 am and urine was collected as spot urine during the following 4 hours. During the 4-hour gavage experiments the mice only had access to water.

**Benzamil injections.** Benzamil is a specific ENaC antagonist (54). Benzamil (0.2 μg/g BW; 0.4 mg/ml dissolved in 0.9% saline with 0.5% DMSO) or vehicle (5% DMSO in 0.9% saline) was administrated via i.p. injections 15 minutes prior to gavage. This dose has been validated to inhibit ENaC efficiently and specifically (18).

**Spot urine in metabolic cages**
Before gavage, the mice were weighed to adjust electrolyte and benzamil dose. Post-gavage animals were placed in metabolic balance cages. Urine samples collected during handling of the mice prior to gavage were used as baseline values. Urine samples were collected as spot urine, as previously described (20).

**KCl infusion**
Mice were given a single water load (25 μl/g BW) as gastric gavage and then anesthetized with an i.p. injection of ketamine and xylazine. Anesthesia was maintained by repetitive bolus injection with a third of the induction dose every 30 minutes. While the mice were placed on a thermostatic controlled heating plate (38°C) an intravenous catheter was inserted in a tail vein and continuous infusion of 300 mOsm saline was started. The lower part of the abdomen was then incised, and the urinary bladder was identified and catheterized. Urine was collected every 5 minutes for flame photometry. The mice were randomly divided in 2 groups. In one group the saline infusion was switched to 300 mOsm KCl after the first 30 minutes at a rate of 4 μl/g BW/h. The infusion rate was titrated to reach [K⁺]p of approximately 6 mM. In the second group the saline infusion was continued throughout the experiment. Simultaneously with changes of infusate, all animals received an i.p. bolus injection of benzamil or vehicle.

**MR blockade**
Eplerenone is a specific MR antagonist with relatively long half-life in vivo (55). Eplerenone tablets (Teva Pharma) were dissolved in tap water (20 mg eplerenone/ml) and administrated by gavage. Mice were given 200 μg/g BW daily (divided into 2 doses of 100 μg/g BW at 9:00 am and 9:00 pm) for 4 days prior to experiments and 100 μg/g BW at 9:00 am on the day of the experiments. Efficacy of the MR blockade using this protocol has previously been verified in our laboratory (53).

**Flame photometry**
The concentrations of Na⁺ and K⁺ in the urine samples were measured using a flame photometer (Model 420 Flame Photometer, Sherwood Scientific) on a 3-mM LiCl background. In order for the samples to be in the detection range, the samples were diluted 1:4 in ddH₂O.

**Plasma electrolyte and aldosterone measurements and tissue harvest**
Forty-five minutes after gavage, mice were anesthetized using ketamine and xylazine i.p. injections. One hour after gavage, blood was sampled by retroorbital puncture using a heparinized capillary tube. Blood was analyzed immediately in an blood gas and osmolyte analyzer. Subsequently, whole blood was extracted from the right atrium of the heart by a heparinized syringe and centrifuged at 4,600 g for 2 minutes. The plasma was kept at –80°C. Plasma aldosterone was measured using an ELISA kit.

After blood collection, mice were perfused with 20 ml PBS via the left atrium of the heart. The kidneys were then removed, decapsulated, and then snap-frozen in liquid nitrogen and kept at –80°C until use.

**Patch-clamp and whole-cell current measurement in native CCD**
The collecting tubules were dissected from the kidney slices, split open, and prepared for apical membrane patch clamp, as previously described (56). An Axon 200A amplifier was used to measure the whole-cell Na⁺ currents in CCD. After forming a gigahm seal, the bath solution was changed to either 1 mM or 5 mM external K⁺. Measurements were made after currents reached steady state (15 minutes after change of bath). ENaC current was assessed as amiloride-inhibitable current at clamp potential of −60 mV. Data were analyzed using the pClamp software system 9.0 (Axon). For inhibitor study experiments, AZD8055 (1 μM) or an equal volume of vehicle was added in the bath solution, after which the bath [K⁺] was changed to
either 1 mM or 5 mM in the presence of AZD8055 or vehicle. Once stable current was reached, whole-cell measurements were made at a holding potential of –60 mV.

Cell culture, transfection, and treatment
mpkCCDc14 (mpkCCD) cells were maintained in modified DMEM/Ham’s F12 (1:1) medium (regular medium) as described previously (57).

HEK-293T, HEK-293T WNK1Δ (a gift from Arohan Subramanya, University of Pittsburgh) (39), and HEK-293T SIN1Δ (32) cells were grown in DMEM (DME H-21, CCFAA005, UCSF Cell Culture Facility) supplemented with 10% FBS and 1% penicillin and streptomycin. Cells were transfected using polyethylenimine (PEI). For experiments with different K⁺ concentrations, DMEM without KCl was used. K⁺-free DMEM was supplemented with KCl, NaCl, or choline chloride to obtain the desired concentrations of K⁺ in the media, as indicated in the figure legends.

Measurement of ENaC-dependent Na⁺ transport
For electrophysiological measurements, mpkCCDc14 cells were seeded on type I collagen–coated filters (Transwell, pore size 0.4 μm, Corning Costar) until the cell monolayers reached transepithelial resistance greater than 1,000 Ω cm². They were then maintained in serum-free plain DMEM for at least 16 hours before treatment with aldosterone (1 μM for 3 hours) to induce endogenous SGK1 expression. For extracellular [K⁺] stimulation/recovery experiments, cells were adapted for at least 2 hours to 1 mM or 3 mM [K⁺]. At t = 0, the medium [K⁺] was increased by addition of KCl or equimolar choline chloride or sodium chloride and incubated for 1 hour prior to measurement of amiloride-sensitive current. Transepithelial resistance and potential difference across the cell monolayer were measured using Millipore Millicell ERS voltohmmeter. The equivalent short-circuit current was calculated using Ohm’s law. Amiloride (10 μM) was added to the medium on the apical side at the end of the experiment to derive the amiloride-sensitive component of the current. Amiloride almost completely (>98%) inhibited the total current, indicating its ENaC dependence. In some experiments, cells were adapted to 5 mM [K⁺] and then transferred to media with different [K⁺] as specified.

In inhibitor study experiments, the inhibitors AZD8055 (1 μM, apical and basolateral sides), GSK650394 (6 μM, apical and basolateral sides), BaCl₂ (100 μM, basolateral side), VU0134992 (10 μM, apical and basolateral sides), or equal volumes of vehicle as the control were added for specified periods of time. Following electrophysiological measurements, cells were harvested and processed for immunoblot analysis.

Immunoblotting
Cultured cells. To determine protein expression levels, Western blot analysis was performed as previously described (7). Briefly, cells were lysed using lysis buffer containing complete protease inhibitor cocktail and PhoSTOP phosphatase inhibitor. Total protein (40 μg) from each cell extract supernatant was electrophoresed in 7.5% polyacrylamide gels. The blots were then probed with primary antibodies followed with horseradish peroxidase–conjugated (HRP-conjugated) secondary antibodies. Each experiment was repeated more than 3 times. The bands corresponding to p-SGK1 and total SGK1 were quantified using ImageJ software (NIH), as previously described (52).

Kidney lysates. Half kidneys were homogenized in 1 ml lysis buffer using a TissueLyser (Qiagen). The supernatant was aspirated and protein concentrations were measured, electrophoresed, and blotted as further described in supplemental information.

Expression constructs
Flag-SGK1 and SIN1-V5 were generated as described previously (58). WT WNK1 (residues 1–491) and WNK1 (residues 1–491) (K233M) were gifts from Melanie Cobb (Department of Pharmacology, UT Southwestern Medical School, Dallas, Texas, USA) and Chou-long Huang (Department of Medicine-Nephrology, University of Iowa Health Care, Iowa City, Iowa, USA) (37).

Statistics
GraphPad Prism and Microsoft Excel were used for data analysis. Comparison between 2 groups was performed by Student’s t test. Comparison between more than 2 groups was analyzed by 1-way ANOVA.
with Bonferroni’s multiple-comparison post hoc test. Comparison of data collected time dependently was done with 2-way ANOVA with Bonferroni’s multiple-comparison post hoc test. The statistical tests used are stated in each figure legend. We presuppose normal/Gaussian distribution of the data but did not test for this, because of the low n (n = 6–8) values in our data. Time-dependent data are shown as mean ± SEM. Time-independent data are shown as bar charts or individual data points in dot plots. Mean ± SEM are depicted as horizontal lines on top of the individual data point. P < 0.05 was considered significant and P values are either shown directly in the figures or symbols for P values are explained in figure legends.

Study approval
Animal experiments were performed in accordance with the Danish legislation on the protection of animals (Dyreforsøgstilsynet license numbers 2013-15-2934-00787 and 2017-15-0201-001166).

Author contributions
MVS, BS, ISJ, PW, NA, SLS, and WHW conducted the experiments and analyzed data. CEG developed the SIN1-KO cell line. CEG and SLS contributed to scientific discussion. MVS, BS, and DP designed the study. MVS, BS, and DP drafted the manuscript.

Acknowledgments
This research was supported by grants from the NIH (R01-DK56695 to DP, R01-DK54983 to WHW), the James Hilton Manning and Emma Austin Manning Foundation to DP, and Collaborative Projects between AIAS and the Aarhus University’s Research Foundation to ISJ. MVS was cofunded by Aarhus University’s Research Foundation and the European Union’s 7th Framework Program under grant agreement number 609033. We thank animal caretakers and technicians, particularly Nina Hald Andersen at the Institute of Biomedicine, Aarhus University. Special thanks go to laboratory technician Karen S. Sørensen. We are grateful to Jens Leipziger, Alicia McDonough (USC), and Roger Nicoll (UCSF) for helpful discussions. We thank Priyanka Rashmi and Prasanna K.R. Allu (UCSF) for helpful scientific discussions. We thank Kevan Shokat (UCSF) for providing PP242 and Sujay Kharade and Jerod S. Denton (Vanderbilt University Medical Center) for providing VU0134992. We also thank Arohan R. Subramanya (University of Pittsburgh) for providing WNK1-KO cells and Melanie Cobb and Chou-long Huang for WNK constructs.

Address correspondence to: David Pearce, Genentech Hall, Rm N272C, University of California, San Francisco, 600 16th St., San Francisco, CA 94158. Phone: 415.476.7015; Email: david.pearce@ucsf.edu.
Or to: Mads Vaarby Sørensen, Dept. of Biomedicine, Aarhus University, Ole Worms Alle 4, bygn 1160, 8000 Arrhus C, Denmark. Phone: 45.25883666; Email: mvs@biomed.au.dk.


